UT Southwestern Medical Center is one of a handful of top research institutions evaluating a promising new medication researchers hope can reduce the severity and frequency of asthma attacks in inner-city children, a population known to have a high prevalence of severe asthma.
Data on fingolimod (FTY720), a new oral immunomodulating drug, reported recently in the New England Journal Medicine shows a relapse rate reduction of more then 50%, compared to placebo, with 77% of people taking Fingolimod remaining relapse-free over the two years of the trial.
Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) approved JANUVIA (sitagliptin phosphate), the first and only DPP-4 inhibitor available in the United States for the treatment of type 2 diabetes. JANUVIA has been approved as monotherapy and as add-on therapy to either of two other types of oral diabetes medications, metformin or thiazolidinediones (TZDs), to improve blood sugar (glucose) control in patients with type 2 diabetes when diet and exercise is not enough. The recommended dose of JANUVIA is 100 mg once daily. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.
A child?s susceptibility to autism is increased with a single gene mutation according to research conducted by, a Vanderbilt-led research team. This discovery has far-reaching implications because this gene, a variant form of a gene called MET, is not just specifically a brain gene but rather a gene which has its effect on multiple systems in the body such as immune function and gut repair.
Soot particles spewing from the exhaust of diesel trucks constitute a major contributor to the alarmingly high rates of asthma symptoms among school-aged children in the South Bronx, according to the results of a five-year study by researchers at New York University’s School of Medicine and Robert F. Wagner Graduate School of Public Service.
The newly established Berkeley Cancer Genome Center, led by members of the Life Sciences Division in the Department of Energy’s Lawrence Berkeley National Laboratory, is one of seven Cancer Genome Characterization Centers to receive awards from the National Cancer Institute and the National Human Genome Research Institute. Earlier today the two institutes, both part of the National Institutes of Health, announced a three-year, $35 million project which will seek to identify important genetic changes involved in lung, brain, and ovarian cancers through genome analysis.
Novartis announced the start of GALIANT, a significant clinical trial set to involve more than 7,500 people in the United States comparing the investigational oral type 2 diabetes medication Galvus? (vildagliptin) with commonly prescribed anti-diabetic oral medicines called thiazolidinediones (TZDs).
On Wednesday, Oct. 25, at 1:00 p.m. EDT, neurosurgeons at Children’s Hospital Boston will remove a brain tumor employing functional mapping of the cortex on a 13-year-old pediatric patient during a live Webcast. Children’s hosts three to four Webcasts annually to showcase its pioneering care and technology to specialists and referring physicians around the world, and to educate consumers on the latest and most innovative medical treatments available.
After all these years, mom was right. She knew broccoli was good for you, she just didn’t know it was this good. “Everyone knows broccoli is good for you and that it contains compounds known to lessen the occurrence of some types of cancer. We want to know how these compounds work and what their specific targets may be,” says Janet V. Cross, Ph.D., Assistant Professor of Pathology at the University of Virginia School of Medicine.
Researchers at Rush University Medical Center found prescription pain medication (PPM) abuse is a rapidly growing problem with surprising and often unpredictable distribution patterns. The research was presented at the Annual Meeting of the American Society for Anesthesiologists in Chicago, October 13, 2006.